Credit Suisse’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Credit Suisse’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-50,000	Closed	-$27K	–	4388
2016 Q3	$27K	Hold	50,000	–	–	﹤0.01%	4052
2016 Q2	$29K	Buy	+50,000	New	+$53.4K	﹤0.01%	4174
2016 Q1	–	Sell	-409,900	Closed	-$1.31M	–	4568
2015 Q4	$1.31M	Sell	409,900 -85,600	-17%	-$412K	﹤0.01%	2604
2015 Q3	$3.1M	Sell	495,500 -412,700	-45%	-$3.86M	﹤0.01%	1941
2015 Q2	$9.02M	Buy	+908,200	New	+$7.95M	0.01%	1319

Other funds holding NWBO

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

CDH

Charles D. Hyman $1.79B AUM 17.18% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

MBT

Montecito Bank & Trust Santa Barbara, California $668M AUM 24.84% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Biegel & Waller Columbia, Maryland $179M AUM 1.6% 1-Year Est. Return

MPI

Mairs & Power Inc St Paul, Minnesota $9.79B AUM 20.6% 1-Year Est. Return

Credit Suisse's NWBO Position: Q4 2016 in Review

Credit Suisse sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q4 2016, closing a stake of 1,898,904 shares — an estimated $1.03M sold.

Credit Suisse first reported a position in NWBO in Q2 2013 and held it in 11 quarters. The position peaked at $17.3M in Q3 2015. 8 funds tracked by Wall St. Rank hold NWBO as of Q4 2016.

Credit Suisse reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q4 2016 after selling out during the quarter.
Credit Suisse sold 1,898,904 Northwest Biotherapeutics, Inc. Common stock shares in Q4 2016, an estimated $1.03M.
Credit Suisse first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q2 2013 and held it in 11 quarters.
Credit Suisse's Northwest Biotherapeutics, Inc. Common stock position peaked at $17.3M in Q3 2015.
8 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q4 2016.

Based on Credit Suisse's 13F filing for Q4 2016, filed 14 Feb 2017.